EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 10, 2008, Pages 1331-1338

  Cavalcante, Jaão L ^a   Khan, Sadiya ^b   Gherghiade, Mihai ^b  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute heart failure syndrome; Fluid overload; Hyponatremia; Talvaptan; Vasopressin antagonist

Indexed keywords

ALDOSTERONE ANTAGONIST; ARGIPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; VASOPRESSIN RECEPTOR;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPONATREMIA; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; REVIEW; WEIGHT REDUCTION; ACUTE DISEASE; AGED; ARTICLE; DRUG ANTAGONISM; EUROPE; FEMALE; MALE; MIDDLE AGED; NORTH AMERICA; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; AGED; BENZAZEPINES; CARDIOVASCULAR AGENTS; EUROPE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; NORTH AMERICA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASOPRESSIN;

EID: 59049087061     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.10.1331     Document Type: Review

References (29)

1. Hugli O, Braun JE, Kim S, Pelletier AJ, Camargo CA Jr. United States emergency department visits for acute decompensated heart failure, 1992 to 2001. Am. J. Cardiol. 96(11), 1537-1542 (2005).
2. Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Heart Fail. Clin. 3(4), 381-387 (2007).
3. Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112(25), 3958-3968 (2005).
4. Kasper EK, Gerstenblith G, Hefter G et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J. Am. Coll. Cardiol. 39(3), 471-480 (2002).
5. Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur. Heart J. 26(7), 644-649 (2005).
6. Hill JA, Yancy CW, Abraham WT. Beyond diuretics: management of volume overload in acute heart failure syndromes. Am. J. Med. 119(12 Suppl. 1), S37-S44 (2006).
7. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol. 46(10), 1785-1791 (2005).
8. Klein L, O'Connpr CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalised patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111(19), 2454-2460 (2005).
9. Gheorghiade M, Rossi JS, Cotts W et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch. Intern. Med. 167(18), 1998 (2007).
10. Gheorghiade M, Abraham WT, Albert NM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur. Heart J. 28(8), 980-988 (2007).
11. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 67(6), 847-858 (2007).
12. Costello-Boerrigter LC, Smith WB, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. 290(2), F273-F278 (2006).
13. Verbalis JG. Vasopressin V2 receptor antagonists. J. Mol. Endocrinol. 29(1), 1-9 (2002).
14. Yamamura Y, Ogawa H, Yamashita H et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105(4), 787-791 (1992).
15. Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287(3), 860-867 (1998).
16. 2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy. J. Card. Fail. 9(5 Suppl. 1), 12 (2003).
17. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107(21), 2690-2696 (2003).
18. Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291(16), 1963-1971 (2004).
19. Gheorghiade M, Konstam MA, Burnett JC Jr. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalised for heart failure: the EVEREST Clinical Status Trials. JAMA 297(12), 1332-1343 (2007).
20. Konstam MA, Gheorghiade M, Burnett JC Jr. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12), 1319-1331 (2007).
21. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355 (20), 2099-2112 (2006).
22. Swedberg K, Bristow MR, Cohn JN et al.; Moxonidine Safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105, 1797-1803 (2002).
23. Mann DL, McMurray JJV, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004).
24. Chung ES, Packer M, Hung Lo K, Fasmanade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation 107, 3133-3140 (2003).
25. Rich S. Endothelin receptor blockers in cardiovascular disease. Circulation 108, 2184-2190 (2003).
26. Coletta AP, Cleland JG. Clinical trials update highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur. J. Heart Fail. 3, 747-750 (2001).
27. Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106, 920-926 (2002).
28. Gheorghiade M, Gottlieb SS, Udelson JE et al. Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 97(7), 1064-1067 (2006).
29. Udelson JE, Orlandi C, Ouyang J et al. Acute hemodynamic effects of Tolvaptan, a vasopressin V2 Receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial. J. Card. Fail. 13(9), 793-794 (2007).